Publikationen in Zusammenarbeit mit Forschern von Erasmus University Medical Center (26)

2023

  1. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

    EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  2. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  3. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  4. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma

    Cancers, Vol. 13, Núm. 6, pp. 1-18

  5. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  2. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets

    Journal of Immunological Methods, Vol. 475

  3. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers

    Journal of Immunological Methods, Vol. 475

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881

2017

  1. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392

  2. Global position paper on cardiovascular regenerative medicine

    European Heart Journal

  3. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  4. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30

  2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 61-72

  3. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  4. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346

  5. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Blood, Vol. 127, Núm. 25, pp. 3165-3174